^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CD38 (CD38 Molecule)

    i
    Other names: CD38, CD38 Molecule, ADP-Ribosyl Cyclase 1, ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1, 2'-Phospho-Cyclic-ADP-Ribose Transferase, 2'-Phospho-ADP-Ribosyl Cyclase, Cyclic ADP-Ribose Hydrolase 1, NAD(+) Nucleosidase, CD38 Antigen (P45), ADPRC 1, 2'-Phospho-ADP-Ribosyl Cyclase/2'-Phospho-Cyclic-ADP-Ribose Transferase, Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase, Cluster Of Differentiation 38, CADPr Hydrolase 1, CD38 Antigen, ADPRC1, T10
    5d
    Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer. (PubMed, Nat Commun)
    Additionally, we validate cTR-T's phenotypic changes following PD-1 blockade therapy in mouse tumor models with artificial antigen. These findings suggest that the phenotypic state and transition of cTR-Ts may reflect their functional potential after tumor infiltration and are associated with therapeutic outcomes of ICIs.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • ITGA1 (Integrin Subunit Alpha 1) • ITGA2 (Integrin Subunit Alpha 2) • TCF7 (Transcription Factor 7)
    6d
    A case of transient monoclonal plasma cell aberrancy following respiratory syncytial virus (RSV) vaccination. (PubMed, J Hematop)
    This case underscores the need for clinical awareness of post-vaccination immunologic phenomena that may mimic plasma cell neoplasm. Recognition of such transient aberrancies can prevent unnecessary invasive investigations and broaden understanding of vaccine-induced immune dynamics.
    Journal
    |
    CD19 (CD19 Molecule) • CD38 (CD38 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule)
    7d
    Immunophenotypic characteristics of plasma cells in POEMS syndrome. (PubMed, Cytometry B Clin Cytom)
    With additional fluorescent channels and enhanced detection sensitivity offering simultaneous analysis of multiple surface markers and intracellular light chains (κ/λ), nine-color flow cytometry enables more precise identification of abnormal plasma cells in POEMS syndrome based on distinct marker expression profiles. CD27, CD28, and CD117 are recommended as potential immunomarkers for flow cytometric analysis in POEMS syndrome.
    Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • CD28 (CD28 Molecule) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
    11d
    Triclonal Gammopathy in Multiple Myeloma with Bleeding Diathesis: A Case Report. (PubMed, Indian J Clin Biochem)
    In plasma cell dyscrasias and lymphoproliferative diseases, monoclonal gammopathies are often observed, while the biclonal variety is less frequent. However, tri clonal gammopathy having a combination of IgM Kappa, IgG Kappa, and IgA Lambda is extremely rare and their clinical significance is unknown.
    Journal • IO biomarker
    |
    CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
    12d
    CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia. (PubMed, Blood Adv)
    We analyzed the T-ALL microenvironment from 40 T-ALL cases treated on the AALL0434 clinical trial and identified a subpopulation of bone-marrow-enriched CCR4+ FOXP3+ T-regulatory cells which express immune checkpoints (PD-1 and TIGIT) and could be targeted with anti-CCR4 therapy. Lastly, we describe the preclinical efficacy of an anti-CCR4 CAR-T in in vitro and in vivo models, paving the way for future translational efforts in chemotherapy refractory T-ALL.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD38 (CD38 Molecule) • CCR4 (C-C Motif Chemokine Receptor 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD5 (CD5 Molecule) • CD7 (CD7 Molecule) • FOXP3 (Forkhead Box P3) • CD2 (CD2 Molecule)
    12d
    A Case of Primary IgG-κ with κ Free Light Chain Plasma Cell Leukemia with Literature Review. (PubMed, Clin Lab)
    For primary plasma cell leukemia, we should pay attention to the changes in the abnormal morphology and number of plasma cells. With the help of bone marrow smear, flow cytometry and other tests, we can make a clear diagnosis as early as possible and actively carry out treatment at an early stage.
    Retrospective data • Review • Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • TNFRSF17 (TNF Receptor Superfamily Member 17) • B2M (Beta-2-microglobulin) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule)
    13d
    Clinical efficacy analysis of seven pediatric patients with Acute myeloid leukemia and the t(16;21)(p11;q22) FUS::ERG fusion gene (PubMed, Zhonghua Yi Xue Yi Chuan Xue Za Zhi)
    The t(16;21)(p11;q22) FUS::ERG fusion gene is rare in pediatric AML and associated with poor prognosis. Allo-HSCT may mitigate the adverse prognostic impact of the FUS::ERG fusion gene and contribute to prolonged survival.
    Retrospective data • Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • ERG (ETS Transcription Factor ERG) • NCAM1 (Neural cell adhesion molecule 1) • FUS (FUS RNA Binding Protein) • ITGAM (Integrin, alpha M) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    cytarabine • etoposide IV • daunorubicin • Synribo (omacetaxine mepesuccinate)
    14d
    RNAseq-based meta-analyses revealed tumor suppressor-inducer fusion events in liver, oral, and ovarian cancer in the Indian population: a cancer cell surviving mechanism. (PubMed, Nucleosides Nucleotides Nucleic Acids)
    WWOX2 serves as a tumor suppressor, whereas FUT1 functions as a promoter of malignancy. The interplay between tumor inducers and suppressors may serve as a survival mechanism for cancer cells, a subject that has received limited research attention.
    Journal • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD38 (CD38 Molecule) • RANBP2 (RAN Binding Protein 2) • ERG (ETS Transcription Factor ERG) • S100A9 (S100 Calcium Binding Protein A9) • TMPRSS2 (Transmembrane serine protease 2) • KRT14 (Keratin 14) • AMBRA1 (Autophagy And Beclin 1 Regulator 1) • GABRP (Gamma-Aminobutyric Acid Type A Receptor Subunit Pi) • RNASE1 (Ribonuclease A Family Member 1) • WWOX (WW Domain Containing Oxidoreductase) • CBX3 (Chromobox 3)
    |
    BCR-ABL1 fusion • TMPRSS2-ERG fusion
    16d
    High PD-1 expression in pre-treatment peripheral lymphocytes associated with poor immune checkpoint inhibitor response in patients with recurrent or metastatic head and neck squamous cell carcinoma. (PubMed, Cancer Immunol Immunother)
    Our findings indicate that high PD-1 expression in PBLs predicts poor treatment outcomes for anti-PD-1 ICIs in patients with RMHNSCC. Dynamic immune monitoring can assist physicians in tailoring personalized therapeutic strategies.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    18d
    Human type-1 innate lymphoid cells control leukemia stem cell differentiation and limit acute myeloid leukemia development. (PubMed, Nat Commun)
    We also identify a human ILC1 subset as Lin-CD127+CD161-CRTH2-CD117- (CD161- ILC1s) that can be generated from umbilical cord blood CD34+ hematopoietic stem cells. This method could provide a reliable source of ILC1s for potential adoptive transfer therapies in AML, offering a therapeutic approach to prolong disease-free survival in AML.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • IFNG (Interferon, gamma) • CD38 (CD38 Molecule) • CD34 (CD34 molecule) • IL7R (Interleukin 7 Receptor) • KLRB1 (Killer Cell Lectin Like Receptor B1) • PTGDR2 (Prostaglandin D2 Receptor 2)
    20d
    Mesothelin Expression in Acute Leukemia: Correlations With Immunophenotype, Cytogenetics, and Mutational Status. (PubMed, Appl Immunohistochem Mol Morphol)
    In AML, it correlated with CD33 expression and inv(16)/t(16;16). In conclusion, mesothelin is rare in ALL but enriched in specific AML subtypes and not prognostic for survival.
    Journal • IO biomarker
    |
    NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • KMT2A (Lysine Methyltransferase 2A) • MSLN (Mesothelin) • CD38 (CD38 Molecule) • KDM6A (Lysine Demethylase 6A) • CD33 (CD33 Molecule) • GATA2 (GATA Binding Protein 2) • PHF6 (PHD Finger Protein 6) • ITGAX (Integrin Subunit Alpha X) • CBLC (Cbl Proto-Oncogene C)
    |
    NPM1 mutation • CBL mutation
    20d
    Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial. (PubMed, Nat Med)
    In summary, our study indicates that early ToD immunochemotherapy substantially improves PFS and OS and is associated with enhanced antitumor CD8+ T cell characteristics compared with late ToD treatment. ClinicalTrials.gov registration: NCT05549037 .
    P3 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)